Albany, US – DelveInsight launched its new report on Neuroendocrine Tumor Market Insights, Epidemiology and Market Forecast 2030
DelveInsight’s “Neuroendocrine Tumors – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Neuroendocrine Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some key facts of the report:1. The total prevalence of NETS was estimated at approximately 453,191 in 2017, for 7MM.2. Among the European countries, Germany had the highest prevalent population of Neuroendocrine Tumors with approximately 49,690 cases, followed by France, which had a prevalent adult population of approximately 40,328 in 2017. On the other hand, Spain had the lowest adult prevalent population of approximately 27,853 cases in 2017.
Key benefits of the report:1. The report covers the descriptive overview of Neuroendocrine Tumors, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies.2. Comprehensive insight has been provided into the Neuroendocrine Tumors epidemiology and treatment in the 7MM.3. Additionally, an all-inclusive account of both the current and emerging therapies for Neuroendocrine Tumors are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.4. A detailed review of Neuroendocrine Tumors market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
Request for sample pages: https://www.delveinsight.com/sample-request/neuroendocrine-tumors-market
“Around 70% of NET patients are functional, and 30% cases non-functional.”
Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumour).
Key pharma companies involved:1. Progenics Pharmaceuticals2. Hutchison MediPharma3. Pfizer4. EpicentRx5. Ignyta6. Amgen7. Antengene8. Mateon Therapeutics
Drugs involved:1. Azedra2. Sulfatinib3. Axitinib4. Entrectinib5. AMG-4796. Carfilzomib7. Fosbretabulin8. RRx-0019. ATG-008
Request for a free sample report: https://www.delveinsight.com/sample-request/neuroendocrine-tumors-market
Table of Contents:
1. Key Insights2. Neuroendocrine Tumor Epidemiology Overview at a Glance3. Neuroendocrine Tumor Disease Background and Overview4. Neuroendocrine Tumor Epidemiology and Patient Population4.1. Key Findings4.2. 7MM Total Neuroendocrine Tumor Prevalent Patient Population4.3. Total Incident Patient Population of Neuroendocrine Tumor4.4. Country Wise Neuroendocrine Tumor Epidemiology4.5. United States4.6. EU5 Countries4.7. Germany4.8. France4.9. Italy4.10. Spain4.11. United Kingdom4.12. Japan5. Neuroendocrine Tumor Treatment Algorithm6. Unmet needs7. Neuroendocrine Tumor Marketed drugs8. Neuroendocrine Tumor Emerging drugs9. Key Cross Competition9.1. Iobenguane I-131: Progenics Pharmaceuticals9.2. 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen9.3. AMG 479: Amgen9.4. Anlotinib: Advenchen Laboratories9.5. Carfilzomib: Amgen9.6. ATG-008: Antengene9.7. Entrectinib: Ignyta9.8. Fosbretabulin: Mateon Therapeutics9.9. Ipilimumab: Bristol-Myers Squibb9.10. Ribociclib: Novartis9.11. Pembrolizumab: Merck9.12. RRx-001: EpicentRx9.13. Axitinib: Pfizer9.14. Cabozantinib: Exelixis9.15. CAM2029: Camurus9.16. Atezolizumab and Bevacizumab: Genentech9.17. Lenvatinib: Eisai9.18. Pasireotide LAR: Novartis9.19. Spartalizumab: Novartis9.20. Tirapazamine: Teclison9.21. Pentarin: Tarveda Therapeutics9.22. Sulfatinib: Hutchison MediPharma9.23. Ibrutinib: Pharmacyclics9.24. Ramucirumab: Eli Lilly9.25. ALT 803: Altor Biosciences9.26. Talimogene laherparepvec: Amgen9.27. Netazepide: Trio Medicines10. Neuroendocrine Tumor 7 Major Market analysis10.1. Key Findings10.2. Neuroendocrine Tumor Market Size in 7MM10.3. Neuroendocrine Tumor Market Outlook by Country10.4. The United States: Market Outlook10.5. EU-5 Countries: Market Outlook10.6. Germany10.7. France10.8. United Kingdom10.9. Spain10.10. Italy10.11. Japan: Market Outlook11. Market Drivers12. Market Barriers13. Appendix14. DelveInsight Capabilities15. Disclaimer16. About DelveInsight
Related Reports:
Neuroendocrine Tumors (NETs) – Epidemiology Forecast to 2030
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NEVADA 89107Country: United StatesWebsite: https://www.delveinsight.com/